Search

Philippe L Durette

from Chagrin Falls, OH
Age ~80
Get Report
Also known as:
Philippe Dr Durette, Phillipe L Durette, Phillip Durette, Phillippe L Durette, Anne P Durette, Philipp Durette, Durette Philipp, Durette Phillipe
Phone and address:
14 Water St, Orange Village, OH 44022
Related to:
Claude John Durette, 87Daniel D Ford, 53Anne P Durette, 82Caroline D Ford, 48Carol D Ford, 75Suzanne L Durette, 47
Connected to:
Howard Durette, 61Jennifer A Durette, 46Susan K Durette, 83Michael J Duretto, 62James P Durey, 80John R Durey, 79Alex M Durfee, 29Dallin S Durfee, 54Darren C Durfee, 31Gerald P Durfee, 67

Philippe Durette Phones & Addresses

  • 14 Water St, Chagrin Falls, OH 44022
  • 187 Pine Ct, New Providence, NJ 07974 (908) 464-7869
  • Hackensack, NJ
  • 14 Water St, Chagrin Falls, OH 44022 (908) 464-7869

Work

Address: Chagrin Falls, OH

Education

Degree: Graduate or professional degree

Ranks

Licence: New Jersey - Active Date: 1994

Professional Records

Lawyers & Attorneys

Philippe Durette Photo 1

Philippe Lionel Durette, Chagrin Falls OH - Lawyer

View page
Address:
Chagrin Falls, OH
(440) 893-9818 (Office)
Licenses:
New Jersey - Active 1994
Philippe Durette Photo 2

Philippe Durette, Whitehouse Station NJ - Lawyer

View page
Office:
One Merck Drive, P.o. Box 100, Whitehouse Station, NJ
ISLN:
909834096
Admitted:
1994

Business Records

Name / Title
Company / Classification
Phones & Addresses
Philippe Durette
Principal
Cd Home Investments LLC
Investor
187 Pne Way, Murray Hill, NJ 07974

Publications

Us Patents

Substituted -Alanine Derivatives As Cell Adhesion Inhibitors

View page
US Patent:
6645939, Nov 11, 2003
Filed:
May 24, 1999
Appl. No.:
09/317789
Inventors:
Philippe L. Durette - New Providence NJ
William K. Hagmann - Westfield NJ
Ihor E. Kopka - Warren NJ
Malcolm MacCoss - Freehold NJ
Sander G. Mills - Scotch Plains NJ
Richard A. Mumford - Red Bank NJ
Plato A. Magriotis - Scotch Plains NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C07K 506
US Classification:
514 19, 514 18, 530331, 548535
Abstract:
-Alanine derivatives of Formula I are antagonists of VLA-4 and/or , and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

Heterocyclic Amide Compounds As Cell Adhesion Inhibitors

View page
US Patent:
6903075, Jun 7, 2005
Filed:
May 28, 1998
Appl. No.:
09/086327
Inventors:
Philippe L. Durette - New Providence NJ, US
Malcolm MacCoss - Freehold NJ, US
William K. Hagmann - Westfield NJ, US
Sander G. Mills - Scotch Plains NJ, US
Richard A. Mumford - Red Bank NJ, US
Jack A. Schmidt - Greenbrook NJ, US
Gail A. Van Riper - Edison NJ, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07K005/06
US Classification:
514 19, 548535
Abstract:
Compounds of Formula I are antagonists of VLA-4 and/or αβ, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.

Nucleoside Aryl Phosphoramidates For The Treatment Of Rna-Dependent Rna Viral Infection

View page
US Patent:
8071568, Dec 6, 2011
Filed:
Dec 28, 2007
Appl. No.:
12/520738
Inventors:
Frank Narjes - Rome, IT
Cristina Gardelli - Rome, IT
Monica Donghi - Rome, IT
Barbara Attenni - Rome, IT
Philippe L. Durette - New Providence NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
Instituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. - Rome
International Classification:
A61K 31/70
C07H 19/10
US Classification:
514 51, 536 268
Abstract:
The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside aryl phosphoramidates alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside aryl phosphoramidates of the present invention. (I).

Nucleoside Cyclic Phosphoramidates For The Treatment Of Rna-Dependent Rna Viral Infection

View page
US Patent:
8148349, Apr 3, 2012
Filed:
Dec 14, 2007
Appl. No.:
12/519038
Inventors:
Malte Meppen - Rome, IT
Frank Narjes - Rome, IT
Barbara Pacini - Rome, IT
Cristina Gardelli - Rome, IT
Philippe L. Durette - New Providence NJ, US
Assignee:
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.P.A. - Rome
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/70
C07H 19/11
US Classification:
514 51, 536 2614
Abstract:
The present invention provides nucleoside cyclic phosphoramidates of formula (I), pharmaceutical compositions comprising the compounds of formula (I) and methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection using the compounds of formula (I).

Nucleoside Derivatives As Inhibitors Of Rna-Dependent Rna Viral Polymerase

View page
US Patent:
20070004669, Jan 4, 2007
Filed:
Jun 17, 2003
Appl. No.:
10/517295
Inventors:
Steven Carroll - Yardley PA, US
David Olsen - Lansdale PA, US
Philippe Durette - New Providence NJ, US
Balkrishen Bhat - Carlsbad CA, US
Prasad Dande - Carlsbad CA, US
Anne Eldrup - Danbury CT, US
International Classification:
A61K 31/7076
A61K 31/7072
C07H 19/04
C07H 19/167
C07H 19/12
US Classification:
514045000, 514049000, 536028300, 536026100, 536027800
Abstract:
The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides For The Treatment Of Rna-Dependent Rna Viral Infection

View page
US Patent:
20080280842, Nov 13, 2008
Filed:
Oct 17, 2005
Appl. No.:
11/664564
Inventors:
Malcolm MacCoss - Freehold NJ, US
David B. Olsen - Lansdale PA, US
Joseph Leone - Tinton Falls NJ, US
Philippe L. Durette - New Providence NJ, US
Assignee:
MERCK & CO., INC. - Rahway NJ
International Classification:
A61K 31/7064
C07H 19/04
A61P 31/12
US Classification:
514 43, 536 272
Abstract:
The present invention provides fluorinated pyrrolo[2,3,d]pyrimidine nucleoside compounds which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to inhibitors of hepatitis C virus (HCV) NS5B polymerase, as precursors to inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such fluorinated pyrrolo[2,3-d]pyrimidine nucleoside alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the fluorinated pyrrolo[2,3-d]pyrimidine nucleoside of the present invention.

1-Substituted Glycopyranosides

View page
US Patent:
42282748, Oct 14, 1980
Filed:
Jul 10, 1978
Appl. No.:
5/922897
Inventors:
Mitree M. Ponpipom - North Plainfield NJ
Robert L. Bugianesi - Colonia NJ
Philippe L. Durette - New Providence NJ
Howard M. Katzen - North Plainfield NJ
Tsung-Ying Shen - Westfield NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07H 506
C07H 508
US Classification:
536 4
Abstract:
The invention disclosed herein relates to novel 1-deoxy-glycopyranosides, preferably 1-deoxy-D-mannopyranosides, having in the 1-position of the pyranoside ring an. omega. -aminoalkylthio,. omega. -aminoalkyloxy or. omega. -aminoalkanoylamino substituent; and to novel processes for preparing these 1-substituted-1-deoxy-glycopyranosides starting with the corresponding tetra-O-acetyl-glycopyranosyl bromide or amine. These. omega. -amino(alkylthio, alkyloxy or alkanoylamino)-1-deoxy-glycopyranosides, and in particular 1-[(6'-aminohexyl)thio or oxy]-1-deoxy-D-mannopyranosides, possess insulin-like activity.

Biarylalkanoic Acids As Cell Adhesion Inhibitors

View page
US Patent:
62915118, Sep 18, 2001
Filed:
Jul 22, 1999
Appl. No.:
9/359015
Inventors:
Philippe L. Durette - New Providence NJ
William K. Hagmann - Westfield NJ
Malcolm MacCoss - Freehold NJ
Sander G. Mills - Scotch Plains NJ
Richard A. Mumford - Red Bank NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07D20708
A61K 3140
US Classification:
514423
Abstract:
Compounds of Formula I are antagonists of VLA-4 and/or. alpha. sub. 4. beta. sub. 7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
Control profile
Philippe L Durette from Chagrin Falls, OH, age ~80 Get Report